A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis

Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Phytomedicine: international journal of phytotherapy and phytopharmacology (Impact Factor: 3.13). 03/2009; 16(5):391-400. DOI: 10.1016/j.phymed.2009.02.002
Source: PubMed


Milk thistle or its purified extract, silymarin (Silybum marianum), is widely used in treating acute or chronic hepatitis. Although silymarin is hepatoprotective in animal experiments and some human hepatotoxic exposures, its efficacy in ameliorating the symptoms of acute clinical hepatitis remains inconclusive. In this study, our purpose was to determine whether silymarin improves symptoms, signs and laboratory test results in patients with acute clinical hepatitis, regardless of etiology.
This is a randomized, placebo-controlled trial in which participants, treating physicians and data management staff were blinded to treatment group. The study was conducted at two fever hospitals in Tanta and Banha, Egypt where patients with symptoms compatible with acute clinical hepatitis and serum alanine aminotransferase (ALT) levels >2.5 times the upper limit of normal were enrolled. The intervention consisted of three times daily ingestion of either a standard recommended dose of 140 mg of silymarin (Legalon, MADAUS GmbH, Cologne, Germany), or a vitamin placebo for four weeks with an additional four-week follow-up. The primary outcomes were symptoms and signs of acute hepatitis and results of liver function tests on days 2, 4 and 7 and weeks 2, 4, and 8. Side-effects and adverse events were ascertained by self-report.
From July 2003 through October 2005, 105 eligible patients were enrolled after providing informed consent. No adverse events were noted and both silymarin and placebo were well tolerated. Patients randomized to the silymarin group had quicker resolution of symptoms related to biliary retention: dark urine (p=0.013), jaundice (p=0.02) and scleral icterus (p=0.043). There was a reduction in indirect bilirubin among those assigned to silymarin (p=0.012), but other variables including direct bilirubin, ALT and aspartate aminotransferase (AST) were not significantly reduced.
Patients receiving silymarin had earlier improvement in subjective and clinical markers of biliary excretion. Despite a modest sample size and multiple etiologies for acute clinical hepatitis, our results suggest that standard recommended doses of silymarin are safe and may be potentially effective in improving symptoms of acute clinical hepatitis despite lack of a detectable effect on biomarkers of the underlying hepatocellular inflammatory process.

Download full-text


Available from: Mohamed Hashem,
  • Source
    • "It is therefore unknown whether After-Effect© will have similar beneficial effects on hangover such as described by Wiese et al. (i.e., reduced scores on nausea, dry mouth, and lack of appetite). Table 1 summarizes the ingredients, suggested mechanism of action, and the corresponding hangover symptoms that showed to benefit from their use [18–29]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A consumer satisfaction study was conducted to examine the effectiveness on hangover of After-Effect(©), a new food supplement dedicated to improve well-being after an occasion of alcohol consumption. N = 113 persons were invited to participate in a home-based open label study to test the effectiveness of After-Effect(©). On a night when they intended to consume alcohol, three pills were taken before alcohol consumption and two pills afterwards, before going to bed. The following day, participants completed a survey on the amount of alcohol consumed, hangover symptom severity, and satisfaction of the product. N = 103 participants completed the study. 88% of participants reported After-Effect(©) to be effective in reducing alcohol hangover. After-Effect(©) significantly improved overall hangover severity, and all individual hangover symptoms, except for palpitations. In addition, a significant reduction (P = 0.0001) in the severity score on concentration problems was reported when using After-Effect(©). No gender differences were observed, and there was no relationship with the number of alcoholic drinks that were consumed. Consumers were satisfied with the product. In conclusion, consumer satisfaction and hangover severity scores suggest that After-Effect(©) may be effective in reducing alcohol hangover. However, controlled, double-blind clinical trials should confirm these findings.
    07/2012; 2012:617942. DOI:10.1155/2012/617942
  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper discusses the effects of the introduction of a personal computer with digital signal processor which can perform high-speed parallel processing with pipeline operation to FEM. The DSP is about 200 times faster than the personal computer with C language. The application of the modified symmetric band-matrix technique makes the calculation time faster than with basic symmetric band-matrix
  • [Show abstract] [Hide abstract]
    ABSTRACT: We use the framework of coarsened data to motivate performing sensitivity analysis in the presence of incomplete data. To perform the sensitivity analysis, we specify pattern-mixture models to allow departures from the assumption of coarsening at random, a generalization of missing at random and independent censoring. We apply the concept of coarsening to address potential bias from missing data and interval-censored data in a randomized controlled trial of an herbal treatment for acute hepatitis. Computer code using SAS PROC NLMIXED for fitting the models is provided.
    Journal of Biopharmaceutical Statistics 11/2009; 19(6):1018-38. DOI:10.1080/10543400903242779 · 0.59 Impact Factor
Show more